VR Logo

Design Therapeutics Inc. (DSGN) download report


Healthcare | Biotechnology & Pharma Research

Design Therapeutics Inc. (DSGN) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions.

IPO Date: 26-Mar-2021

Pres, CEO & Director: Dr. João Siffert M.D.

Chief Operating Officer: Dr. Sean Jeffries Ph.D.

Listing: NASDAQ: DSGN

Country: United States

Headquarters: Carlsbad, CA

Website: https://www.designtx.com

Key Facts

Market cap: $866.30 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-43.28 Mln

Cash: $371.22 Mln

Total Debt: $3.52 Mln

Insider's Holding: 36.84%

Liquidity: Low

52 Week range: $9.61 - 24.08

Shares outstanding: 55,782,400

Stock Performance

Time Period Design Therapeutics (DSGN) S&P BSE Sensex S&P Small-Cap 600
YTD-28.77-9.49-17.79
1 month17.40-2.87-2.72
3 months-10.77-8.59-12.17
1 Year-33.110.81-15.82
3 Years--10.397.14
5 Years--11.116.20
10 Years--12.0010.33
As on 24-Jun-2022